Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age



Status:Completed
Conditions:Influenza
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - 49
Updated:4/21/2016
Start Date:October 2014
End Date:May 2015

Use our guide to learn which trials are right for you!

Double-Blind, Randomized, Active-Controlled Comparison of the Immunogenicity and Safety of Flublok® Quadrivalent Versus IIV4 in Healthy, Medically Stable Adults 18-49 Years of Age

Randomized, double-blind trial of safety and immunogenicity of Flublok Quadrivalent versus
Inactivated Influenza Vaccine (IIV4) in 1350 healthy, medically stable adults 18-49 years of
age. Serum samples for Hemagglutinin Inhibition titers will be determined pre- and 28 days
post-vaccination. Subjects will be followed for 6 months after vaccination for serious
and/or medically-attended adverse events.

As the spectrum of influenza vaccines rapidly evolves to quadrivalent formulations with the
intention of offering broader protection to include both lineages of influenza B strains, it
is appropriate to transition Flublok from a trivalent to a quadrivalent formulation. The
demonstration of non-inferior post-vaccination Hemagglutination Inhibition Assay (HAI)
Geometric Mean Titers (GMTs) to antigens in the Flublok Quadrivalent formulation compared to
those of the matching antigens in a US - approved IIV4 is intended to support licensure of
Flublok Quadrivalent for the adult population for which Flublok trivalent is currently
approved. The comparison of safety and reactogenicity of Flublok Quadrivalent to that of
IIV4 is expected to confirm a similar safety profile.

Inclusion Criteria:

- Ambulatory, in good health or medically stable

- Able to understand and comply with planned study procedures

- Provide written informed consent

- Negative urine pregnancy test within 24 hours prior to vaccination (women of
child-bearing potential)

Exclusion Criteria:

- Prior serious or severe reaction to influenza vaccine

- Known contraindication to either study vaccine

- Receipt of any other influenza vaccine within 180 days prior to enrollment

- Plan to receive another licensed influenza or other vaccine during the duration of
this study

- Receipt of any significant new diagnosis, medication (licensed or investigational),
or licensed vaccine within 30 days prior to enrollment in this study

- Underlying disease or therapeutic intervention that might adversely affect the immune
response

- Plans to participate in any investigation involving an investigational product during
this study.

- Pregnant, lactating or planning to become pregnant within 30 days of study vaccine.

- Any clinical or social circumstance that in the opinion of the investigator could
interfere with compliance with study procedures or interfere with the interpretation
We found this trial at
10
sites
Omaha, Nebraska 68134
?
mi
from
Omaha, NE
Click here to add this to my saved trials
1709 S Rock Rd
Wichita, Kansas 67207
316-689-6629
?
mi
from
Wichita, KS
Click here to add this to my saved trials
Austin, Texas 78705
?
mi
from
Austin, TX
Click here to add this to my saved trials
Bellevue, Nebraska 68005
?
mi
from
Bellevue, NE
Click here to add this to my saved trials
801 Monterey Street
Coral Gables, Florida 33134
?
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Dakota Dunes, South Dakota 57049
?
mi
from
Dakota Dunes, SD
Click here to add this to my saved trials
Fort Worth, Texas 76135
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Metairie, Louisiana 70006
?
mi
from
Metairie, LA
Click here to add this to my saved trials
Sacramento, California 95822
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Savannah, Georgia 31406
?
mi
from
Savannah, GA
Click here to add this to my saved trials